We're making our third sale of this health-care stock since its earnings sell-off.
Get this delivered to your inbox, and more info about our products and services.
We're adding to a consumer name and starting a position in another. Plus, we're trimming a rallying drug stock.
The stock's drop this week isn't tied to fundamentals.
We're taking half of the cash raised from the sale to add to one of the portfolio's recent spinoffs.
We're making our second buy in a household product giant.
Our trading restrictions had prevented us from executing these purchases earlier.
We're also downgrading the stock in conjunction with the sale.
